MDxHealth SA (NASDAQ:MDXH) Short Interest Down 68.8% in June

MDxHealth SA (NASDAQ:MDXH) saw a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 33,040 shares, a decrease of 68.8% from the June 15th total of 106,013 shares. Based on an average daily volume of 911,575 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company’s stock are sold short.

MDxHealth Price Performance

Shares of MDXH traded down $0.01 during mid-day trading on Tuesday, reaching $0.42. The company’s stock had a trading volume of 632,664 shares, compared to its average volume of 467,889. MDxHealth has a 12-month low of $0.40 and a 12-month high of $5.33. The stock has a market cap of $20.55 million, a PE ratio of -0.64 and a beta of 1.43. The company’s 50 day moving average is $0.80 and its 200 day moving average is $2.29.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. As a group, sell-side analysts anticipate that MDxHealth will post -0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MDXH. Lake Street Capital decreased their price objective on MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. William Blair cut shares of MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Wall Street Zen downgraded shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. TD Cowen reiterated a “buy” rating and set a $1.50 price target (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, MDxHealth presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.62.

Institutional Investors Weigh In On MDxHealth

Several hedge funds and other institutional investors have recently bought and sold shares of MDXH. Intesa Sanpaolo Wealth Management acquired a new position in MDxHealth in the fourth quarter valued at $36,000. Lido Advisors LLC purchased a new stake in shares of MDxHealth in the 3rd quarter valued at about $48,000. Squarepoint Ops LLC acquired a new stake in shares of MDxHealth in the 4th quarter valued at about $51,000. Jefferies Financial Group Inc. purchased a new position in MDxHealth during the 3rd quarter worth approximately $53,000. Finally, Balyasny Asset Management L.P. acquired a new position in MDxHealth during the fourth quarter worth approximately $68,000.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.